Még nem toboroz
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· 2/3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
NCT07355218· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360· 2. fázis· CSL Behring· Forrás
Toboroz
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336· 2. fázis· Genentech, Inc.· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849· 2. fázis· CSL Behring· Forrás
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
WATER IV Prostate Cancer
NCT06651632· PROCEPT BioRobotics· Forrás
Toboroz
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT06435156· 2. fázis· University of Dundee· Forrás
Toboroz
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
NCT06588686· 2. fázis· Vicore Pharma AB· Forrás
Fut, nem toboroz
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914· AbbVie· Forrás
Fut, nem toboroz
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· 3. fázis· Genmab· Forrás
Toboroz
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
NCT06343805· 1. fázis· Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840· 1. fázis· Epsilogen Ltd· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733· 3. fázis· Ivy Brain Tumor Center· Forrás
Toboroz
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505· 1/2. fázis· Gilead Sciences· Forrás
Toboroz
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135· 3. fázis· Kartos Therapeutics, Inc.· Forrás
Toboroz
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
NCT05635162· 2. fázis· University College, London· Forrás
Fut, nem toboroz
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535· 3. fázis· United Therapeutics· Forrás
Toboroz
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
HTL0039732 in Participants With Advanced Solid Tumours
NCT05944237· 1/2. fázis· Cancer Research UK· Forrás
Fut, nem toboroz
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
NCT05466799· 2. fázis· OncoSil Medical Limited· Forrás
Toboroz
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure
NCT05568069· University Hospital Southampton NHS Foundation Trust· Forrás
Toboroz
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904· 3. fázis· Iovance Biotherapeutics, Inc.· Forrás
Fut, nem toboroz
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778· 3. fázis· AbbVie· Forrás
Toboroz
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· 2/3. fázis· Cancer Research UK· Forrás
Toboroz
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562· 3. fázis· Jazz Pharmaceuticals· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013· 2. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886· 3. fázis· Celcuity Inc· Forrás
Fut, nem toboroz
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/
NCT05421806· NEAT ID Foundation· Forrás
Fut, nem toboroz
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
NCT05456685· 2. fázis· AbbVie· Forrás
Showing 50 of 71.